CLINICAL TRIALS PROFILE FOR INGREZZA
✉ Email this page to a colleague
All Clinical Trials for ingrezza
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03325010 ↗ | Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome | Completed | Neurocrine Biosciences | Phase 2 | 2017-10-05 | This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a total of 12 weeks of treatment in pediatric subjects with TS. |
| NCT03444038 ↗ | Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome | Completed | Neurocrine Biosciences | Phase 2 | 2018-02-08 | This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome. |
| NCT03530293 ↗ | Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome | Terminated | Neurocrine Biosciences | Phase 2 | 2018-04-16 | This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS. |
| NCT03732534 ↗ | Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome | Terminated | Neurocrine Biosciences | Phase 2 | 2018-10-17 | This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 for the treatment of TS for pediatric participants who have taken part in a Phase 2 NBI-98854 study. |
| NCT05157100 ↗ | Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia | Enrolling by invitation | The Orthopedic Foundation | Phase 4 | 2021-10-19 | STUDY OF INGREZZA (VALBENAZINE) FOR THE TREATMENT OF CERVICAL DYSTONIA |
| NCT05207085 ↗ | Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults | Not yet recruiting | Neurocrine Biosciences | Phase 2 | 2022-02-01 | This trial aims to evaluate the efficacy, safety and tolerability of valbenazine, titrated to the subject's optimal dose of 40mg or 80mg, administered once daily, for 12 weeks, for the treatment of trichotillomania (TTM) in a double blind placebo controlled design study. After week 12, subjects will begin a 12-week, open-label portion of the study. During the open-label portion of the study, all subjects will receive the study drug at their optimal dose. The primary endpoint of these studies will be the change from baseline of placebo vs. active scores utilizing the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) at the end of Week 12. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ingrezza
Condition Name
Clinical Trial Locations for ingrezza
Trials by Country
Clinical Trial Progress for ingrezza
Clinical Trial Phase
Clinical Trial Sponsors for ingrezza
Sponsor Name
